On the morning of September 4, Kingsley Biotech announced on the Hong Kong Stock Exchange that the company proposed to split Probio Technology Limited and list its shares independently on the main board of the Stock Exchange. Details on the proposed spin-off are yet to be implemented. After the proposed spin-off is completed, the company will continue to hold a controlling interest in BoboBio. It will remain a subsidiary of the company, and its financial results will continue to be consolidated into the Group's financial statements.

On the morning of September 4, Kingsley Biotech announced on the Hong Kong Stock Exchange that the company proposed to split Probio Technology Limited and list its shares independently on the main board of the Stock Exchange. Details on the proposed spin-off are yet to be implemented. After the proposed spin-off is completed, the company will continue to hold a controlling interest in Boombio. It will still be a subsidiary of the company, and its financial results will continue to be consolidated into the group's financial statements.